Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Genomics shed light on targeted treatment for myeloma

Nikhil Munshi • 5 Oct 2018
ESH MM 2018
Multiple Myeloma Venetoclax

Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, reveals how genomics can be used to inform clinical practice for targeted multiple myeloma (MM) treatment at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France. Dr Munshi outlines what genomics can reveal about clonal heterogeneity, as well as how genomics informs research and clinical practice for smoldering myeloma. Overall, current and new sequencing techniques provide deeper understanding of MM biology.

More from Nikhil Munshi

1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023
1:05
Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi • 11 Dec 2023
2:42
Immunotherapeutic approaches to overcoming drug resistance in venetoclax-exposed patients with MM
Nikhil Munshi • 11 Dec 2023
2:02
Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals